Events, By Category and Date:
» Go to news mainPermissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada
Posted by nte on
February 24, 2023
in
In Print
Image credit: New York Times
Sud A, McGee M, Mintzes B, Herder M. Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada. Int J Drug Policy. 2022 Jul;105:103749. doi: 10.1016/j.drugpo.2022.103749. Epub 2022 May 26. PMID: 35643048.
Recent News
- On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data
- Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada
- Matthew Herder Resigns from Patented Medicine Prices Review Board
- Fair pricing of “old” orphan drugs: considerations for Canada’s orphan drug policy
- Podcast or Perish: Episode 040: Françoise Baylis
- Bioethicist Françoise Baylis asks why humans think 'they can just take everything'
- Killam Prize winners discuss research in Canada
- World‑renowned Dalhousie bioethicist and battery pioneer win prestigious Killam Prize